The therapeutic potential of Ma'aljobon, a whey product, in primary hypertension: A double-blind randomized controlled trial

  • سال انتشار: 1404
  • محل انتشار: مجله گیاهان دارویی ابن سینا، دوره: 15، شماره: 1
  • کد COI اختصاصی: JR_AJP-15-1_006
  • زبان مقاله: انگلیسی
  • تعداد مشاهده: 113
دانلود فایل این مقاله

نویسندگان

Asie Shojaii

Department of Traditional Pharmacy, Institute for Studies in Medical History, Persian and Complementary Medicine, School of Persian Medicine, Iran University of Medical Sciences, Tehran, Iran

Roshanak Ghods

Department of Traditional Medicine, Institute for Studies in Medical History, Persian and Complementary Medicine, School of Persian Medicine, Iran University of Medical Sciences, Tehran, Iran

Fataneh Hashem-Dabaghian

Department of Traditional Medicine, Institute for Studies in Medical History, Persian and Complementary Medicine, School of Persian Medicine, Iran University of Medical Sciences, Tehran, Iran

Maryam Navabzadeh

Department of Persian Medicine, Birjand University of Medical Sciences, Birjand, Iran

Tooba Kazemi

Cardiovascular Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran

Morné Weyers

African Medicines Innovations and Technologies Development (AMITD), Indigenous knowledge based Medicines and Innovations Centre, School of Clinical Medicine, Faculty of Health Sciences, University of the Free State, Bloemfontein ۹۳۰۰, South

Motlalepula G. Matsabisa

Department of Pharmacology, African Medicines Innovations and Technologies Development (AMITD), Indigenous knowledge based Medicines and Innovations Centre, School of Clinical Medicine, Faculty of Health Sciences, University of the Free State,

چکیده

Objective: Ma’aljobon is used in Persian medicine (PM) as a natural antihypertensive product. This study aimed to evaluate the hypotensive effect of Ma’aljobon in patients with uncontrolled grade ۱ primary hypertension (HTN).Materials and Methods: This double-blind, placebo-controlled clinical trial included ۱۱۴ patients (۲۰-۸۰ years) with uncontrolled grade ۱ primary HTN. After obtaining informed consent, the participants were randomly divided into two groups and administered with ۲۵g of Ma’aljobon or maltodextrin twice daily for six weeks. Systolic and diastolic blood pressures (SBP and DBP, respectively) were analyzed.Results: A total of ۹۷ patients (۵۲.۳±۱۰.۷ years, %۵۳.۶ female) completed the study. In the Ma’aljobon group, SBP decreased from ۱۵۰.۳±۱۲.۳ to ۱۳۰.۶±۱۲.۱ mm Hg, and DBP decreased from ۹۳.۳±۸.۲ to ۸۰.۱±۶.۶ mm Hg (p< ۰.۰۰۱). In the control group, SBP decreased from ۱۴۷.۶±۱۱.۲ to ۱۳۸.۷±۱۴.۴ mm Hg, and DBP decreased from ۸۶.۶±۷.۷ to ۸۲.۲±۸.۲ mm Hg (p< ۰.۰۰۱). There was a significant difference in the changes of SBP and DBP between the two groups over time (p< ۰.۰۰۱). No adverse events were observed.Conclusion: Ma’aljobon has a stronger hypotensive effect than placebo in patients with HTN and can be recommended as an add-on therapy for uncontrolled HTN.

کلیدواژه ها

Hypertension, Persian Medicine, Whey Proteins, Traditional Medicine

اطلاعات بیشتر در مورد COI

COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.

کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.